Nordson Earnings Call Transcripts
Fiscal Year 2026
-
Record Q2 sales and earnings driven by broad-based organic growth, strong backlog, and robust cash flow. Guidance for FY26 was raised on continued demand momentum, with all segments contributing and strategic M&A supporting future growth.
-
Record Q1 sales and earnings driven by strong semiconductor demand and broad-based segment growth, with robust cash flow and increased full-year guidance. Margins held steady despite mix and FX headwinds, and capital deployment remained disciplined.
Fiscal Year 2025
-
Record sales and earnings were achieved in fiscal 2025, with strong cash flow enabling share repurchases, debt reduction, and dividend increases. Segment performance was mixed, but order backlogs and end-market trends support a positive 2026 outlook.
-
Q3 sales rose 12% year-over-year to $742 million, with strong contributions from the Atrion acquisition and double-digit organic growth in advanced technology. Record free cash flow enabled debt reduction and share repurchases, while FY25 guidance was modestly improved despite ongoing market uncertainties.
-
Second quarter sales grew 5% year-over-year to $683 million, with strong performance in advanced technology and medical segments, aided by the Atrion acquisition. EBITDA margin reached 32%, and Q3 guidance projects continued growth despite trade uncertainties.
-
Q1 sales declined 3% year-over-year to $615M, with strong margins and cash flow despite soft demand in electronics and industrial markets. Backlog and order entry improved, and the Atrion acquisition contributed to growth. Guidance remains at the lower end for sales, but profit targets are reaffirmed.
Fiscal Year 2024
-
Record sales and EBITDA were achieved in 2024, driven by acquisitions and operational efficiency. Fiscal 2025 guidance calls for 2%-7% sales growth and up to 8% adjusted EPS growth, with Atrion as a key contributor. Cautious outlook reflects macro and end-market uncertainties.
-
The company outlined a five-year plan targeting 6%-8% annual revenue growth and 10%-12% EPS growth, driven by the Ascend Strategy and NBS Next framework. Portfolio transformation, disciplined M&A, and operational excellence position all segments for above-market growth, with strong cash flow supporting continued investment and flexibility.
-
Third quarter sales rose 2% year-over-year to $662 million, with strong IPS growth and ARAG contribution offsetting softness in medical and electronics. Adjusted EPS was $2.41, and the Atrion acquisition expands the medical portfolio and addressable market. Guidance for FY24 remains unchanged at flat to 2% revenue growth and $9.45–$9.65 EPS.